{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:25:52Z","timestamp":1791170752741,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.molmed.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T05:31:42Z","timestamp":1435642302000},"page":"504-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Gene therapy for neurodegenerative diseases"],"prefix":"10.1016","volume":"21","author":[{"given":"Deirdre M.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Boulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2015.06.001_bib0610","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.03.004","article-title":"Adeno-associated virus (AAV) gene therapy for neurological disease","volume":"69","author":"Weinberg","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.molmed.2015.06.001_bib0615","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0079-6123(09)17513-1","article-title":"Gene therapy for neurodegenerative diseases based on lentiviral vectors","volume":"175","author":"Nanou","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib0620","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0625","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1227\/NEU.0b013e31825ca05f","article-title":"Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes","volume":"71","author":"Riley","year":"2012","journal-title":"Neurosurgery"},{"key":"10.1016\/j.molmed.2015.06.001_bib0630","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9.GFP in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0635","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0640","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.molmed.2015.06.001_bib0645","doi-asserted-by":"crossref","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2015.06.001_bib0650","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrneurol.2014.252","article-title":"Axial disability and deep brain stimulation in patients with Parkinson disease","volume":"11","author":"Fasano","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0655","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mt.2013.281","article-title":"Parkinson's disease gene therapy: success by design meets failure by efficacy","volume":"22","author":"Bartus","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0660","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0665","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0670","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.05.026","article-title":"Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease","volume":"44","author":"Bartus","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2015.06.001_bib0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molmed.2015.06.001_bib0680","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","article-title":"Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)","volume":"58","author":"Herzog","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2015.06.001_bib0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","article-title":"Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u2018clinical proof-of-concept\u2019 for AAV-neurturin (CERE-120) in Parkinson's disease","volume":"34","author":"Bartus","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.molmed.2015.06.001_bib0690","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2015.06.001_bib0695","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2015.06.001_bib0700","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0705","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2015.06.001_bib0710","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0715","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/hum.2011.162","article-title":"Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum","volume":"23","author":"San Sebastian","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0720","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/mt.2012.1","article-title":"Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease","volume":"20","author":"Cederfjall","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0725","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/srep02157","article-title":"Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease","volume":"3","author":"Cederfjall","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2015.06.001_bib0730","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","article-title":"AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model","volume":"248","author":"Ren","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/brb3.117","article-title":"Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease","volume":"3","author":"Back","year":"2013","journal-title":"Brain Behav."},{"key":"10.1016\/j.molmed.2015.06.001_bib0740","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/exnr.2002.8006","article-title":"Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer","volume":"177","author":"Georgievska","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0745","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/01926230701481899a","article-title":"Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys","volume":"35","author":"Hovland","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0750","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/mt.2009.196","article-title":"Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0755","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1460-9568.2003.02456.x","article-title":"Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"17","author":"Rosenblad","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.molmed.2015.06.001_bib0760","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/mt.2013.169","article-title":"Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease","volume":"21","author":"Quintino","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0765","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.chembiol.2010.07.009","article-title":"A general chemical method to regulate protein stability in the mammalian central nervous system","volume":"17","author":"Iwamoto","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0770","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.expneurol.2014.04.013","article-title":"Dissection of genetic factors associated with amyotrophic lateral sclerosis","volume":"262","author":"Leblond","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0775","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0780","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1523\/JNEUROSCI.2037-14.2014","article-title":"Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex","volume":"34","author":"Thomsen","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2015.06.001_bib0785","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0790","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0795","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pharmthera.2013.10.009","article-title":"Gene and protein therapies utilizing VEGF for ALS","volume":"141","author":"Keifer","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0800","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","article-title":"Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration","volume":"28","author":"Oosthuyse","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib0805","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/mt.2010.206","article-title":"AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice","volume":"18","author":"Dodge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0810","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/17482968.2011.574142","article-title":"Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats","volume":"12","author":"Kliem","year":"2011","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.molmed.2015.06.001_bib0815","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/mt.2010.271","article-title":"CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit","volume":"19","author":"Henriques","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0820","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1172\/JCI62636","article-title":"Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS","volume":"122","author":"Butovsky","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2015.06.001_bib0825","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1093\/hmg\/ddt261","article-title":"Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice","volume":"22","author":"Koval","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib0830","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mrrev.2014.05.001","article-title":"Nonsense-mediated decay in genetic disease: friend or foe? Mutation research","volume":"762","author":"Miller","year":"2014","journal-title":"Rev. Mutat. Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib0835","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/gt.2014.101","article-title":"Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis","volume":"22","author":"Jackson","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0840","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.biopsych.2011.06.019","article-title":"Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease","volume":"71","author":"Grothe","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.molmed.2015.06.001_bib0845","doi-asserted-by":"crossref","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.molmed.2015.06.001_bib0850","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mcn.2015.02.016","article-title":"Current and future implications of basic and translational research on amyloid-beta peptide production and removal pathways","volume":"66","author":"Bohm","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2015.06.001_bib0855","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/070674371405901202","article-title":"Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease","volume":"59","author":"Hogan","year":"2014","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.molmed.2015.06.001_bib0860","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.molmed.2015.06.001_bib0865","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/mt.2013.118","article-title":"Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease","volume":"21","author":"Murphy","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0870","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/mtna.2014.30","article-title":"Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies","volume":"3","author":"Sud","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2015.06.001_bib0875","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2005.03.010","article-title":"Metabolism of amyloid-beta peptide and Alzheimer's disease","volume":"108","author":"Iwata","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0880","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/srep01472","article-title":"Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice","volume":"3","author":"Iwata","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2015.06.001_bib0885","doi-asserted-by":"crossref","first-page":"e59626","DOI":"10.1371\/journal.pone.0059626","article-title":"Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice","volume":"8","author":"Carty","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2015.06.001_bib0890","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3233\/JAD-2010-1298","article-title":"Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices","volume":"19","author":"Marwarha","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.molmed.2015.06.001_bib0895","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neurobiolaging.2012.08.003","article-title":"Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta","volume":"34","author":"Doherty","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.molmed.2015.06.001_bib0900","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2014.07.004","article-title":"Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders","volume":"64","author":"Farr","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.molmed.2015.06.001_bib0905","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/gt.2013.85","article-title":"Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP\/PS1 mice","volume":"21","author":"Perez-Gonzalez","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0910","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pneurobio.2010.04.002","article-title":"Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases","volume":"91","author":"Knuesel","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0915","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neurobiolaging.2007.08.011","article-title":"Age-related accumulation of Reelin in amyloid-like deposits","volume":"30","author":"Knuesel","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.molmed.2015.06.001_bib0920","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1523\/JNEUROSCI.0418-10.2010","article-title":"Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice","volume":"30","author":"Kocherhans","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2015.06.001_bib0925","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3233\/JAD-2012-112069","article-title":"Reelin depletion is an early phenomenon of Alzheimer's pathology","volume":"30","author":"Herring","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.molmed.2015.06.001_bib0930","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuroscience.2012.07.038","article-title":"F-spondin gene transfer improves memory performance and reduces amyloid-beta levels in mice","volume":"223","author":"Hafez","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.molmed.2015.06.001_bib0935","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.1091230","article-title":"ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease","volume":"304","author":"Lustbader","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.molmed.2015.06.001_bib0940","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2174\/1567205011666141107150938","article-title":"Caspase-3 short hairpin RNAs: a potential therapeutic agent in neurodegeneration of aluminum-exposed animal model","volume":"11","author":"Zhang","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib0945","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.4103\/1673-5374.135317","article-title":"A viral vector expressing hypoxia-inducible factor 1 alpha inhibits hippocampal neuronal apoptosis","volume":"9","author":"Chai","year":"2014","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib0950","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/cns.12312","article-title":"Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3\u00d7Tg-AD mice and MC65 cells","volume":"20","author":"Revilla","year":"2014","journal-title":"CNS Neurosci. Therapeutics"},{"key":"10.1016\/j.molmed.2015.06.001_bib0955","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.15252\/emmm.201404228","article-title":"Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice","volume":"6","author":"Pascual-Lucas","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2015.06.001_bib0960","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2015.77","article-title":"Spinal muscular atrophy \u2013 recent therapeutic advances for an old challenge","author":"Faravelli","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0965","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1517\/14712598.2012.711306","article-title":"Update on gene and stem cell therapy approaches for spinal muscular atrophy","volume":"12","author":"Donnelly","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0970","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/hum.2014.011","article-title":"Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy","volume":"25","author":"Passini","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0975","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose\u2013response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib0980","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0985","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","article-title":"Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery","volume":"19","author":"Bevan","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib0990","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib0995","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2015.06.001_bib1000","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ygeno.2015.01.007","article-title":"Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7","volume":"105","author":"Staropoli","year":"2015","journal-title":"Genomics"},{"key":"10.1016\/j.molmed.2015.06.001_bib1005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ncl.2013.04.006","article-title":"Clinical neurogenetics: autosomal dominant spinocerebellar ataxia","volume":"31","author":"Shakkottai","year":"2013","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.molmed.2015.06.001_bib1010","doi-asserted-by":"crossref","first-page":"e52396","DOI":"10.1371\/journal.pone.0052396","article-title":"Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado\u2013Joseph disease transgenic mice","volume":"8","author":"Nobrega","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2015.06.001_bib1015","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","article-title":"Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice","volume":"21","author":"Rodriguez-Lebron","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1020","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib1025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1030","doi-asserted-by":"crossref","first-page":"e95362","DOI":"10.1371\/journal.pone.0095362","article-title":"RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration","volume":"9","author":"Ramachandran","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molmed.2015.06.001_bib1035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/humc.2015.002","article-title":"A review of gene therapy in canine and feline models of lysosomal storage disorders","volume":"26","author":"Bradbury","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.molmed.2015.06.001_bib1040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.beem.2014.08.005","article-title":"Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments","volume":"29","author":"Pastores","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2015.06.001_bib1045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2015.06.001_bib1050","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1060","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1070","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic leukodystrophy: disease spectrum and approaches for treatment","volume":"29","author":"van Rappard","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2015.06.001_bib1090","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.2012.015","article-title":"Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/gt.2014.17","article-title":"Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector","volume":"21","author":"Miyake","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","article-title":"Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations","volume":"68","author":"Valstar","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2015.06.001_bib1105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1110","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/mt.2015.9","article-title":"Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice","volume":"23","author":"Duncan","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1115","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2015.06.001_bib1120","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","article-title":"Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer","volume":"23","author":"Ruzo","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ymgme.2010.01.004","article-title":"Identification and characterization of a novel homozygous deletion in the alpha-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB)","volume":"100","author":"Champion","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molmed.2015.06.001_bib1130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood\u2013brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1135","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/hmg\/ddu727","article-title":"Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy","volume":"24","author":"Ribera","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib1140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.molmed.2015.06.001_bib1145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2015.06.001_bib1150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/bmt.2011.239","article-title":"Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I","volume":"47","author":"Wolf","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.molmed.2015.06.001_bib1155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1227\/NEU.0000000000000157","article-title":"Comparison of endovascular and intraventricular gene therapy with adeno-associated virus-alpha-l-iduronidase for Hurler disease","volume":"74","author":"Janson","year":"2014","journal-title":"Neurosurgery"},{"key":"10.1016\/j.molmed.2015.06.001_bib1160","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1165","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jnr.20798","article-title":"Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice","volume":"83","author":"Denny","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib1170","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1093\/hmg\/ddr364","article-title":"Adeno-associated virus-mediated expression of beta-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain","volume":"20","author":"Sargeant","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2015.06.001_bib1175","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415569908","article-title":"AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system","volume":"7","author":"Rockwell","year":"2015","journal-title":"ASN Neuro."},{"key":"10.1016\/j.molmed.2015.06.001_bib1180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/gt.2014.108","article-title":"Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease","volume":"22","author":"McCurdy","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2015.06.001_bib1185","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","article-title":"Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients","volume":"80","author":"Bartus","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2015.06.001_bib1190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"Suppl. 1","key":"10.1016\/j.molmed.2015.06.001_bib1195","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.metabol.2014.10.034","article-title":"Biomarkers in the diagnosis and management of Alzheimer's disease","volume":"64","author":"Wurtman","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.molmed.2015.06.001_bib1200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2014.10.031","article-title":"Use of biomarkers in ALS drug development and clinical trials","volume":"1607","author":"Bakkar","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2015.06.001_bib1205","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer's disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2015.06.001_bib1210","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","article-title":"Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions","volume":"85","author":"Magdalinou","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.molmed.2015.12.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000}}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491415001185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491415001185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:15:03Z","timestamp":1761462903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491415001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1471491415001185"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2015.06.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}